Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma

[1] Matthay KK(1999)Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group N Engl J Med 341 1165-1173

[2] Villablanca JG(2008)High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial Lancet Oncol 9 247-256

[3] Seeger RC(2008)Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children’s Oncology Group Pediatr Blood Cancer 51 747-753

[4] Stram DO(2011)Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project J Clin Oncol 29 3286-3292

[5] Harris RE(2010)123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis J Clin Endocrinol Metab 95 2596-2606

[6] Ramsay NK(2009)Development of a semi-quantitative I-123 mIBG reporting method in high risk neuroblastoma J Nucl Med 50 1379-2491

[7] Pearson AD(2003)Correlation of early metastatic response by123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma J Clin Oncol 21 2486-525

[8] Pinkerton CR(2011)18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis J Nucl Med 52 519-874

[9] Lewis IJ(2006)Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma Pediatr Blood Cancer 47 865-61

[10] Imeson J(2012)Comparison of (18)F-dopa PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study Eur J Nucl Med Mol Imaging 39 57-e78

[1] Matthay KK(1999)Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group N Engl J Med 341 1165-1173

[2] Villablanca JG(2008)High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial Lancet Oncol 9 247-256

[3] Seeger RC(2008)Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children’s Oncology Group Pediatr Blood Cancer 51 747-753

[4] Stram DO(2011)Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project J Clin Oncol 29 3286-3292

[5] Harris RE(2010)123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis J Clin Endocrinol Metab 95 2596-2606

[6] Ramsay NK(2009)Development of a semi-quantitative I-123 mIBG reporting method in high risk neuroblastoma J Nucl Med 50 1379-2491

[7] Pearson AD(2003)Correlation of early metastatic response by123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma J Clin Oncol 21 2486-525

[8] Pinkerton CR(2011)18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis J Nucl Med 52 519-874

[9] Lewis IJ(2006)Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma Pediatr Blood Cancer 47 865-61

[10] Imeson J(2012)Comparison of (18)F-dopa PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study Eur J Nucl Med Mol Imaging 39 57-e78